Replies to post #423468 on NorthWest Biotherapeutics Inc (NWBO)

[scotty3371]

79 cents.

[biosectinvestor]

1) buying on the open market gives money to traders, not the company. If the company needs to get from point A to point D, and can't, that money was wasted.
2) an investor like Fyfe is investing and ensuring the preservation of his capital at the same time, which is not the deal for the buyer on the open market for equity. He will likely get paid no matter what, with a substantial upside. Many investors who have much money already, prefer those kinds of deals to the buy the equity and pray deals that we ordinary investors must do to get into these companies on the public markets. Even if the results are not great or it failed, he'd get paid most likely. Someone buying at today's price probably would not get their money back soon with a profit, and not get the option of profiting much more for the same capital, with a lot less risk.

[exwannabe]

scooty, if John started buying shares from the open market for that 15M dollars, where would have the share price ended $5, $7? But now he can get it for a lot cheaper say $2 at TLD with a 12% discount. Which one is better for him.

Interesting that you think the PPS after TLD will be around $2.

[skitahoe]

I don't doubt that under confidentiality he knows essentially what will be in the TLD statement. What he doesn't know is, how and when will it be presented.

If in fact the TLD statement simultaneously announce the Journal publication and the submission of a BLA, no telling how high the share price may gap to. I don't believe that $10 would be out of the question.

I'm not saying this is happening, just that the company is doing much while in a quiet period, no telling how they'll roll out everything once they're ready to do so.

I'm of the belief that if major media coverage jumped on the information being rolled out, the share price could gap well above anything investors here believe. Certainly a gap well into double digit share prices will eventually retrench some of the gain, but it's possible that even a 50% retrenchment won't take the shares below $10. I'm not saying this will be the case, I have no idea how they intend to roll out everything, but if major media were running stories on how a vaccine may be the answer to most solid cancers, how high is up.

Many years ago an article in the NY Times took a dollar a share company to over $100 before it fell back to earth. Dr. Judah Folkman was curing mice with cancer, but the article made it sound like if he were left alone, in two years he could be doing it in humans. Clearly it didn't happen, and now curing humans may not get as much attention as he did with mice, but no telling what happens if the media calls attention to the company at the time they release the TLD.

Gary